Trastuzumab emtansine and trastuzumab deruxtecan use in three patients with ERBB2-amplified rare tumors
Rare tumors respond to targeted antibody drug treatments
This retrospective case series evaluated three patients with ERBB2-amplified rare tumors, including periampullary, salivary duct, and poorly…
Three patients with rare, aggressive cancers saw significant tumor shrinkage after receiving targeted antibody drug therapies.
